Обзорная статья

International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases

Kalpana GuptaDepartment of Medicine, Veterans Affairs Boston Health Care System and Boston University School of Medicine, Boston, MassachusettsThomas M. HootonDepartment of Medicine, University of Miami Miller School of Medicine, University of Miami, Miami FloridaKurt G. NaberTechnical University of Munich, Munich, GermanyBjörn WulltLund University Hospital, Lund, SwedenRichard ColganDepartment of Family and Community Medicine, University of Maryland, Baltimore, MarylandLoren G. MillerDivision of Infectious Diseases, Harbor-UCLA Medical Center, TorranceGregory J. MoranDepartment of Emergency Medicine and Division of Infectious Diseases Olive View-UCLA Medical Center, Slymar, CaliforniaLindsay E. NicolleDepartment of Internal Medicine and Department of Medical Mirobiology University of Manitoba, Winnipeg, CanadaRaul RazInfectious Diseases Unit, Ha'Emek Medical Center, Afula, and Rappaport Faculty of Medicine, Technion, Haifa, IsraelAnthony J. SchaefferDeptartment of urology, Northwestern University, Chicago, IllinoisDavid E. SoperDepartments of Obstetrics and Gynecology and Medicine, Medical University of South Carolina, Charleston, South Carolina

2011en

ABI

Аннотация

A Panel of International Experts was convened by the Infectious Diseases Society of America (IDSA) in collaboration with the European Society for Microbiology and Infectious Diseases (ESCMID) to update the 1999 Uncomplicated Urinary Tract Infection Guidelines by the IDSA. Co-sponsoring organizations include the American Congress of Obstetricians and Gynecologists, American Urological Association, Association of Medical Microbiology and Infectious Diseases-Canada, and the Society for Academic Emergency Medicine. The focus of this work is treatment of women with acute uncomplicated cystitis and pyelonephritis, diagnoses limited in these guidelines to premenopausal, non-pregnant women with no known urological abnormalities or co-morbidities. The issues of in vitro resistance prevalence and the ecological adverse effects of antimicrobial therapy (collateral damage) were considered as important factors in making optimal treatment choices and thus are reflected in the rankings of recommendations.

Перевод пока недоступен

Идентификаторы

DOI: 10.1093/cid/ciq257

Цитирования и источники

Цитирований: 3Использованных источников: 0

Показатели — AkademScholar